The 1,4-dihydropyridines (DHPs), a class of drugs, possess a wide variety of biological and pharmacological actions, have represented one of the most important groups of calcium-channel-modulating agents and have experienced widespread use in the treatment of cardiovascular disease. Moreover, it has been demonstrated that DHPs could prove to be highly important as multidrug-resistance-reversing agents in cancer chemotherapy. Recent reports suggest that this class also has other notable activities, particularly as antimycobacterial and anticonvulsant agents. Finally, it might be possible for the DHP motif to serve as a scaffold for other pharmacological applications
More than 40 years after their introduction in therapy, 1,4-dihydropyridines (DHPs) are still amongs...
More than 40 years after their introduction in therapy, 1,4-dihydropyridines (DHPs) are still amongs...
More than 40 years after their introduction in therapy, 1,4-dihydropyridines (DHPs) are still amongs...
The 1,4-dihydropyridines (DHPs), a class of drugs, possess a wide variety of biological and pharmaco...
1,4-Dihydropyridines were introduced in the last century for the treatment of coronary diseases. The...
1,4-Dihydropyridines were introduced in the last century for the treatment of coronary diseases. The...
1,4-Dihydropyridines were introduced in the last century for the treatment of coronary diseases. The...
1,4-Dihydropyridines were introduced in the last century for the treatment of coronary diseases. The...
1,4-Dihydropyridines were introduced in the last century for the treatment of coronary diseases. The...
1,4-Dihydropyridines were introduced in the last century for the treatment of coronary diseases. The...
Since the pioneering studies of Fleckenstein and co-workers, L-Type Calcium Channel (LTCC) blockers ...
Since the pioneering studies of Fleckenstein and co-workers, L-Type Calcium Channel (LTCC) blockers ...
Since the pioneering studies of Fleckenstein and co-workers, L-Type Calcium Channel (LTCC) blockers ...
none8Since the pioneering studies of Fleckenstein and co-workers, L-Type Calcium Channel (LTCC) bloc...
Multidrug resistance (MDR) is defined as resistance of tumor cells to the cytotoxic action of multip...
More than 40 years after their introduction in therapy, 1,4-dihydropyridines (DHPs) are still amongs...
More than 40 years after their introduction in therapy, 1,4-dihydropyridines (DHPs) are still amongs...
More than 40 years after their introduction in therapy, 1,4-dihydropyridines (DHPs) are still amongs...
The 1,4-dihydropyridines (DHPs), a class of drugs, possess a wide variety of biological and pharmaco...
1,4-Dihydropyridines were introduced in the last century for the treatment of coronary diseases. The...
1,4-Dihydropyridines were introduced in the last century for the treatment of coronary diseases. The...
1,4-Dihydropyridines were introduced in the last century for the treatment of coronary diseases. The...
1,4-Dihydropyridines were introduced in the last century for the treatment of coronary diseases. The...
1,4-Dihydropyridines were introduced in the last century for the treatment of coronary diseases. The...
1,4-Dihydropyridines were introduced in the last century for the treatment of coronary diseases. The...
Since the pioneering studies of Fleckenstein and co-workers, L-Type Calcium Channel (LTCC) blockers ...
Since the pioneering studies of Fleckenstein and co-workers, L-Type Calcium Channel (LTCC) blockers ...
Since the pioneering studies of Fleckenstein and co-workers, L-Type Calcium Channel (LTCC) blockers ...
none8Since the pioneering studies of Fleckenstein and co-workers, L-Type Calcium Channel (LTCC) bloc...
Multidrug resistance (MDR) is defined as resistance of tumor cells to the cytotoxic action of multip...
More than 40 years after their introduction in therapy, 1,4-dihydropyridines (DHPs) are still amongs...
More than 40 years after their introduction in therapy, 1,4-dihydropyridines (DHPs) are still amongs...
More than 40 years after their introduction in therapy, 1,4-dihydropyridines (DHPs) are still amongs...